ocaratuzumab
Ocaratuzumab is a humanized monoclonal antibody designed for the treatment of cancer and autoimmune disorders. The antibody is engineered for enhanced affinity to the CD20 antigen on B-lymphocytes, increased antibody-dependent cell-mediated cytotoxicity (ADCC), and for improved treatment of low-affinity FcγRIIIa allotypes. — Wikipedia
Clinical trial activity
2 trials · 13 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2006 (NCT00354926)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20BINDING AGENT
B-lymphocyte antigen CD20 binding agent
Acts through engagement of immune effector cells, directly activating intracellular death signaling pathways and/or activation of the complement cascade.
- Integrin beta-2INHIBITOR
ITGB2 inhibitor
Mediates antibody-dependent cell-mediated cytotoxicity (ADCC) (10-fold increase in ADCC than rituximab).
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOcaratuzumab ↗
- ChEMBLCHEMBL2109665 ↗
- ChEMBLCHEMBL2109346 ↗
Also known as
- ame133
- ame 133
- ame-133
- ame-133v
- ly2469298
- ly2469298
- ly 2469298
- ly-2469298
- ly-2469298
- ocaratuzumab
- ocaratuzumab
- ocaratuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01858181 | Phase 1 | Jan 1, 2015 | Mentrik Biotech, LLC |
| NCT00354926 | Phase 1 | Jul 1, 2006 | Applied Molecular Evolution, Nevada Cancer Institute, Rush University, SCRI Development Innovations, Stanford University, Temple University, University of Alabama, University of California, Los Angeles, University of Iowa, University of Pittsburgh, University of Rochester, University of Virginia |
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Applied Molecular Evolution | For profit | 1 | 1 | 1 | 2006 |
| Mentrik Biotech, LLC | For profit | 1 | 1 | 1 | 2015 |
| Nevada Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Rush University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2006 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Alabama | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Virginia | Academic/Hospital | 1 | 0 | 1 | 2006 |